IRF-4 Functions As a Tumor Suppressor in Early B-cell Development

Overview

Journal Blood

Publisher Elsevier

Specialty Hematology

Date 2008 Aug 21

PMID 18713947

Citations 29

Authors

Jaime Acquaviva

Xiaoren Chen

Ruibao Ren

Affiliations

Soon will be listed here.

Abstract

Interferon regulatory factor-4 (IRF-4) is a hematopoietic cell-restricted transcription factor important for hematopoietic development and immune response regulation. It was also originally identified as the product of a proto-oncogene involved in chromosomal translocations in multiple myeloma. In contrast to its oncogenic function in late stages of B lymphopoiesis, expression of IRF-4 is down-regulated in certain myeloid and early B-lymphoid malignancies. In this study, we found that the IRF-4 protein levels are increased in lymphoblastic cells transformed by the BCR/ABL oncogene in response to BCR/ABL tyrosine kinase inhibitor imatinib. We further found that IRF-4 deficiency enhances BCR/ABL transformation of B-lymphoid progenitors in vitro and accelerates disease progression of BCR/ABL-induced acute B-lymphoblastic leukemia (B-ALL) in mice, whereas forced expression of IRF-4 potently suppresses BCR/ABL transformation of B-lymphoid progenitors in vitro and BCR/ABL-induced B-ALL in vivo. Further analysis showed that IRF-4 inhibits growth of BCR/ABL+ B lymphoblasts primarily through negative regulation of cell-cycle progression. These results demonstrate that IRF-4 functions as tumor suppressor in early B-cell development and may allow elucidation of new molecular pathways significant to the lymphoid leukemogenesis by BCR/ABL. The context dependent roles of IRF-4 in oncogenesis should be an important consideration in developing cancer therapies targeting IRF-4.

Citing Articles

Advancing the genetic engineering toolbox by combining AsCas12a knock-in mice with ultra-compact screening.

Jin W, Deng Y, La Marca J, Lelliott E, Diepstraten S, Konig C Nat Commun. 2025; 16(1):974.

PMID: 39885149 PMC: 11782673. DOI: 10.1038/s41467-025-56282-2.

DFF-ChIP: a method to detect and quantify complex interactions between RNA polymerase II, transcription factors, and chromatin.

Spector B, Santana J, Pufall M, Price D Nucleic Acids Res. 2024; 52(18):e88.

PMID: 39248105 PMC: 11472042. DOI: 10.1093/nar/gkae760.

Integrative alternative splicing analysis reveals new prognosis signature in B-cell acute lymphoblastic leukemia.

Zhuo Z, Wang J, Zhang Y, Meng G Int J Biol Sci. 2024; 20(11):4496-4512.

PMID: 39247833 PMC: 11380455. DOI: 10.7150/ijbs.98899.

IRF4 Participates in Pulmonary Fibrosis Induced by Silica Particles through Regulating Macrophage Polarization and Fibroblast Activation.

Jiao B, Zhang Q, Jin C, Yu H, Wu Q Inflammation. 2023; 47(1):45-59.

PMID: 37938462 DOI: 10.1007/s10753-023-01890-7.

A multimorphic mutation in IRF4 causes human autosomal dominant combined immunodeficiency.

Fornes O, Jia A, Kuehn H, Min Q, Pannicke U, Schleussner N Sci Immunol. 2023; 8(79):eade7953.

PMID: 36662884 PMC: 10825898. DOI: 10.1126/sciimmunol.ade7953.

References

Ortmann C, Burchert A, Holzle K, Nitsche A, Wittig B, Neubauer A . Down-regulation of interferon regulatory factor 4 gene expression in leukemic cells due to hypermethylation of CpG motifs in the promoter region. Nucleic Acids Res. 2006; 33(21):6895-905. PMC: 1310901. DOI: 10.1093/nar/gki1001. View

Jabbour E, Faderl S, Kantarjian H . Adult acute lymphoblastic leukemia. Mayo Clin Proc. 2005; 80(11):1517-27. DOI: 10.4065/80.11.1517. View

Goldman J, Melo J . Chronic myeloid leukemia--advances in biology and new approaches to treatment. N Engl J Med. 2003; 349(15):1451-64. DOI: 10.1056/NEJMra020777. View

Hu Y, Swerdlow S, Duffy T, Weinmann R, Lee F, Li S . Targeting multiple kinase pathways in leukemic progenitors and stem cells is essential for improved treatment of Ph+ leukemia in mice. Proc Natl Acad Sci U S A. 2006; 103(45):16870-5. PMC: 1629087. DOI: 10.1073/pnas.0606509103. View

Ottmann O, Wassmann B . Treatment of Philadelphia chromosome-positive acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2005; :118-22. DOI: 10.1182/asheducation-2005.1.118. View

Roumiantsev S, de Aos I, Varticovski L, Ilaria R, Van Etten R . The src homology 2 domain of Bcr/Abl is required for efficient induction of chronic myeloid leukemia-like disease in mice but not for lymphoid leukemogenesis or activation of phosphatidylinositol 3-kinase. Blood. 2001; 97(1):4-13. DOI: 10.1182/blood.v97.1.4. View

Klein F, Feldhahn N, Mooster J, Sprangers M, Hofmann W, Wernet P . Tracing the pre-B to immature B cell transition in human leukemia cells reveals a coordinated sequence of primary and secondary IGK gene rearrangement, IGK deletion, and IGL gene rearrangement. J Immunol. 2004; 174(1):367-75. DOI: 10.4049/jimmunol.174.1.367. View

Mittrucker H, Matsuyama T, Grossman A, Kundig T, Potter J, Shahinian A . Pillars Article: Requirement for the Transcription Factor LSIRF/IRF4 for Mature B and T Lymphocyte Function. . 1997. 275: 540-543. J Immunol. 2017; 199(11):3717-3720. View

Hao S, Ren R . Expression of interferon consensus sequence binding protein (ICSBP) is downregulated in Bcr-Abl-induced murine chronic myelogenous leukemia-like disease, and forced coexpression of ICSBP inhibits Bcr-Abl-induced myeloproliferative disorder. Mol Cell Biol. 2000; 20(4):1149-61. PMC: 85233. DOI: 10.1128/MCB.20.4.1149-1161.2000. View

10.

Ren R . The molecular mechanism of chronic myelogenous leukemia and its therapeutic implications: studies in a murine model. Oncogene. 2002; 21(56):8629-42. DOI: 10.1038/sj.onc.1206090. View

11.

LeBien T . Fates of human B-cell precursors. Blood. 2000; 96(1):9-23. View

12.

Kanno Y, Levi B, Tamura T, Ozato K . Immune cell-specific amplification of interferon signaling by the IRF-4/8-PU.1 complex. J Interferon Cytokine Res. 2005; 25(12):770-9. DOI: 10.1089/jir.2005.25.770. View

13.

Deininger M, Druker B . Specific targeted therapy of chronic myelogenous leukemia with imatinib. Pharmacol Rev. 2003; 55(3):401-23. DOI: 10.1124/pr.55.3.4. View

14.

Klein U, Casola S, Cattoretti G, Shen Q, Lia M, Mo T . Transcription factor IRF4 controls plasma cell differentiation and class-switch recombination. Nat Immunol. 2006; 7(7):773-82. DOI: 10.1038/ni1357. View

15.

Pui C, Jeha S . New therapeutic strategies for the treatment of acute lymphoblastic leukaemia. Nat Rev Drug Discov. 2007; 6(2):149-65. DOI: 10.1038/nrd2240. View

16.

Holtschke T, Lohler J, Kanno Y, Fehr T, Giese N, Rosenbauer F . Immunodeficiency and chronic myelogenous leukemia-like syndrome in mice with a targeted mutation of the ICSBP gene. Cell. 1996; 87(2):307-17. DOI: 10.1016/s0092-8674(00)81348-3. View

17.

Cuenco G, Ren R . Cooperation of BCR-ABL and AML1/MDS1/EVI1 in blocking myeloid differentiation and rapid induction of an acute myelogenous leukemia. Oncogene. 2002; 20(57):8236-48. DOI: 10.1038/sj.onc.1205095. View

18.

Iida S, Rao P, Butler M, Corradini P, Boccadoro M, Klein B . Deregulation of MUM1/IRF4 by chromosomal translocation in multiple myeloma. Nat Genet. 1997; 17(2):226-30. DOI: 10.1038/ng1097-226. View

19.

Schmidt M, Hochhaus A, Nitsche A, Hehlmann R, Neubauer A . Expression of nuclear transcription factor interferon consensus sequence binding protein in chronic myeloid leukemia correlates with pretreatment risk features and cytogenetic response to interferon-alpha. Blood. 2001; 97(11):3648-50. DOI: 10.1182/blood.v97.11.3648. View

20.

Ren R . Mechanisms of BCR-ABL in the pathogenesis of chronic myelogenous leukaemia. Nat Rev Cancer. 2005; 5(3):172-83. DOI: 10.1038/nrc1567. View